{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.95","upperLimit":"6.54","value":"2.89"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group.","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The intended reverse Kaplan-Meier model could not be built with so few patients in the group.","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"1"}],"units":"Participants"}],"description":"PFS was defined as the time from the first treatment of AUTO4 to documented disease progression/relapse or death due to any cause.\n\nIf a patient did not have relapse or death due to any reason prior to data cut-off, PFS was censored at the date of the last adequate assessment by default.\n\nPatients who received protocol specified anti-cancer treatment post AUTO4 infusion were ignored in the main analysis.\n\nPatients who proceeded to SCT after AUTO4 infusion were censored at the time of SCT (including the conditioning regimen for SCT).\n\nPatients who received new non-protocol anticancer therapies other than SCT were censored as the date of last adequate assessment prior to the new therapy.\n\nPatients who experienced event after missing two or more scheduled disease assessments were censored at the date of last adequate assessment prior to the event","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients who received an infusion of AUTO4 and who were not censored.","id":"OG000","title":"All Treated Patients Evaluable for PFS"},{"description":"Patients received 25x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG001","title":"Phase I Dose Escalation - Cohort 1"},{"description":"Patients received 75x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG002","title":"Phase I Dose Escalation - Cohort 2"},{"description":"Patients received 225x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG003","title":"Phase I Dose Escalation - Cohort 3"},{"description":"Patients received 450x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG004","title":"Phase I Dose Escalation - Cohort 4"},{"description":"Patients received 225x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG005","title":"Phase I Dose Escalation With Modified Manufacturing Process - Cohort 3"},{"description":"Patients received 450x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG006","title":"Phase I Dose Escalation With Modified Manufacturing Process - Cohort 4"},{"description":"Patients received 900x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG007","title":"Phase I Dose Escalation With Modified Manufacturing Process - Cohort 5"}],"paramType":"MEDIAN","populationDescription":"Data for PFS were pooled for analysis because the number of patients was \\<5 for all of the groups and the intended reverse Kaplan-Meier model cannot be built with such a small sample size","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Evaluate Progression-free Survival (PFS) Following Treatment With AUTO4.","type":"SECONDARY","unitOfMeasure":"months"}